Inclusion body myositis studies

The following list of published research is intended to serve as a resource for study of inflammatory myopathies.

2023

• Stephanie Hunn, Lindsay Alfano, Michelle Seiffert, Conrad C. Weihl. Exploring hand and upper limb function in patients with inclusion body myositis (IBM). Neuromuscular Disorders 2023; 33: 643–650. doi: 10.1016/j.nmd.2023.06.009.
• Machado, McDermott, Blaettler, Sundgreen, Amato, Ciafaloni, Freimer, Gibson, Jones, Levine, Lloyd, Mozaffar, Shaibani, Wicklund, Rosholm, Carstensen, Bonefeld, Jørgensen, Phonekeo, Heim, Herbelin, Barohn, Hanna, Dimachkie, on behalf of the Arimoclomol in IBM Investigator Team of the Neuromuscular Study Group. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2023; 22: 900–11. doi: 10.1016/S1474-4422(23)00275-2.

2022

• Lloyd TE, Britson KA, Ling JP, Braustein K, Montagne JM, Kastenschmidt JM, Wilson A, Ikenaga C, Tsao W, Pinal-Fernandez I, Mozaffar T, Corse AM, Villalta SA, Russell KA, Reed N, Wagner KR, Ostrow LW, Larman HB, and Wong PC. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Science Translational Medicine. 19 Jan 2022; 14:628. doi: 10.1126/scitranslmed.abi9196.
• Ikenaga C, Date D, Kanagawa M, Mitsui J, Ishiura H, Yoshimura J, Pinal-Fernandez I, Mammen A, Lloyd TE, Tsuji S, Shimizu J, Toda T, and Goto J. Muscle transcriptomics shows overexpression of cadherin 1 in inclusion body myositis. Ann Neurol. 2022 Mar;91(3):317-328. DOI: 10.1002/ana.26304

2018

• Lilleker. JB. Advances in the early diagnosis and therapy of IBM. Current Opinion in Rheumatology, 2018; July 31. doi: 10.1097/BOR.0000000000000537.
• Mozaffar T, Wencel M, Goyal NA, Philips C, Olsen C, Munoz K, Mannaa A, Villalta A. Kv1.3 expression on effector memory T-cells in sporadic inclusion body myositis: Potential for targeted immunotherapy with dalazatide. Poster presented at American Academy of Neurology annual meeting, April 26, 2018.
• Allison Keshishian, Steven A. Greenberg, Neetu Agashivala, Onur Baser, Kristen Johnson.  Health care costs and comorbidities for patients with inclusion body myositis. Current Medical Research and Opinion. 2018; 34(9): 1679–1685. DOI: 10.1080/03007995.2018.1486294.

2017

• Mendell et al. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Molecular Therapy, 2017 April; 25(4). doi:10.1016/j.ymthe.2017.02.015.
• Lilleker JB, Rietveld a, Pye SR, Mariampillai K, Benveniste o, Peeters MTJ, Miller JAL, Hanna MG, Machado PM, Parton MJ, Gheorghe KR, Badrising UA, Lundberg IE, Sacconi S, Herbert MK, McHugh NJ, Lecky BRF, Brierley C, Hilton-Jones D, Lamb JA, Roberts ME, Cooper RG, Saris CGJ, Pruijn GJM, Chinoy H, van Engelen BGM, On behalf of all UKMYONET contributors. Cytosolic 50-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Ann Rheum Dis 2017;0:1-7. doi:10.1136/annrheumdis-2016-210282
• Olivier Benveniste, Jean-Yves Hogrel, Melanie Annoussamy, Damien Bachasson, Aude Rigolet, Laurent Servais, Joe-Elie Salem, Baptiste Hervier, Oceane Landon Cardinal, Kuberaka Mariampillai, Jean-Sebastien Hulot, Pierre Carlier, and Yves Allenbach. Rapamycin vs. placebo for the treatment of inclusion body myositis: Improvement of the 6-Minute Walking Distance, a functional scale, the FVC and Muscle Quantitative MRI. Abstract presented at ACR/ARHP Annual Meeting, November 7, 2017.

2016

• Greenberg SA, Pinkus JL, Amato AA, Kristensen T, Dorfman DM.  Association of inclusion body myositis with T cell large granular lymphocytic leukemia.  BRAIN 2016: 139; 1348–1360. doi:10.1093/brain/aww024.
• D. Hilton-Jones and S. Brady.  Diagnostic criteria for inclusion body myositis.  Journal of Internal Medicine.  DOI: 10.1111/joim.12480.
• Conrad C. Weihl, Robert H. Baloh, Youjin Lee, Tsui-Fen Chou, Sara K. Pittman, Glenn Lopate, Peggy Allred, Jennifer Jockel-Balsarotti, Alan Pestronk, and Matthew B. Harmsa.  Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis.  National Center for Biotechnology Information (NCBI).  Neuromuscul Disord. 2015 Apr; 25(4): 289–296. Published online 2015 Jan 6. doi: 10.1016/j.nmd.2014.12.009.
• Anthony A. Amato, Umesh Badrising, Olivier Benveniste, Merrilee Needham, Hector Chinoy, Min Wu, Barbara Koumaras, Ana de Vera, Dimitris A. Papanicolaou, and Michael G. Hanna. A Randomized, Double-Blind, Placebo-Controlled Study of Bimagrumab in Patients with Sporadic Inclusion Body Myositis. 2016 ACR/ARHP Annual Meeting. 2016 Oct. 19.

2015

• Pedro M. Machado, Mhoriam Ahmed, Stefen Brady, Qiang Gang, Estelle Healy, Jasper M. Morrow, Amanda C. Wallace, Liz Dewar, Gita Ramdharry, Matthew Parton, Janice L. Holton, Henry Houlden, Linda Greensmith, and Michael G. Hanna.  Ongoing Developments in Sporadic Inclusion Body Myositis.  Curr Rheumatol Rep. 2014; 16: 477.  Published online Nov 18, 2014. doi: 10.1007/s11926-014-0477-9.
• Barghout Vm, VEB HealthCare, Morristown, NJ; DeMuro C, Williams V, and Price, M, RTI Health Solutions, Research Triangle Park, NC: Goldberg B, The Myositis Association Alexandria, VA; Lowes L, Nationwide Children’s Hospital, Columbus, OH; B Tseng, Novartis Pharmaceuticals, East Hanover, NJ.  Resource utilization.  US-based Sample of Patients with Sporadic Inclusion Body Myositis (sIBM).
• Patrick Cherin, Jean-Christophe Delain, Christophe de Jaeger, and Jean-Charles Cravec.  Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases.  NCBI.  Case Rep Neurol. 2015 Sep-Dec; 7(3): 227–232.  Published online 2015 Nov 5. doi: 10.1159/000441490.
• A. David Paltiel, Einar Ingvarsson, Donald K. K. Lee, Richard L. Leff, Richard J. Nowak, Kurt D. Petschke, Seth Richards-Shubik, Ange Zhou, Martin Shubik, and Kevin C. O’Connor. Demographic and clinical features of inclusion body myositis in North America. Muscle & Nerve. doi: 10.1002/mus.24562.
• Olivier Benveniste, Werner Stenzel, David Hilton-Jones, Marco Sandri, Olivier Boyer, and Baziel G. M. van Engelen. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: The inflammatory egg comes before the degenerative chicken. Acta Neuropathol. 2015; 129(5): 611–624. doi: 10.1007/s00401-015-1384-5.

2014

• FL Mastaglia.  Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC FL Mastaglia.  Acta Myol. Oct 2009; 28(2): 66–71.
• Ke Li, Chuanqiang Pu, Xusheng Huang, Jiexiao Liu, Yanling Mao, and Xianghui Lu.  Proeteomic study of inclusion body myositis.  Proteome Sci. 2014; 12(1): 45.  Published online Sep 12, 2014. doi: 10.1186/s12953-014-0045-2.
• Qiang Gang, Conceição Bettencourt and Henry Houlden.  Sporadic inclusion body myositis: the genetic contributions to the pathogenesis.   Orphanet J Rare Dis.  2014; 9:88.
• A.R. Santos, M.T. Neves, Jr., and M.S. Aoki.  BLOOD FLOW RESTRICTED RESISTANCE TRAINING ATTENUATES MYOSTATIN GENE EXPRESSION IN A PATIENT WITH INCLUSION BODY MYOSITIS.  Biol Sport.  June 2014; 31(2):  121-124.
• THOMAS SCHRöDER, JOHANN FUCHSS and FRANK HANISCH.  Eosinophils in hereditary and inflammatory myopathies.  Acta Myologica.  Dec 2013;  32(3): 148-153.
• Stefen Brady, Waney Squier, and Janice L Holton.  A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis.  BMJ Open.  2014; 4(4); e004552.
• Yves Allenbach, Wahiba Chaara, and Olivier Benveniste.  Th1 Response and Systemic Treg Deficiency in Inclusion Body Myositis.   PLoS One.  2014; 9(3): e88788.
• Andrea Cortese, Vincent Plagnol, and Pietro Fratta.  Widespread RNA metabolism impairment in sporadic inclusion body myositis TDP43-proteinopathy.  Neurobiology of Aging.  Jun 2014; 35(6): 1491-1498.
• Luke Lam, MD, Stephen Scheper, DO, and Kore K Liow, MD, FACP, FAAN.  Inclusion Body Myositis: A Case of Bilateral Extremity Weakness.  Hawaii J Med Public Health.  Dec 2013; 72(12): 417-420.
• Jian Zhu, H. Benjamin Larman, and Stephen J. Elledge.  Protein interaction mapping with ribosome-displayed using PLATO ORF libraries.  Nature Protocols.  Jan 2014: 9(1): 90-103.
• Masahiro Nakamori, Tetsuya Takahashi, and Masayasu Matsumoto.  Molecular Markers for Granulovacuolar Degeneration Are Present in Rimmed Vacuoles.  PLoS One.  2013; 8(11): e80995.
• Michael O. Harris-Love, Joseph A. Shrader, and Marinos Dalakas.  Are Repeated Single-Limb Heel Raises and Manual Muscle Testing Associated With Peak Plantar-Flexor Force in People With Inclusion Body Myositis?  Physical Therapy.  Apr 2014; 94(4): 543-552.
• Annie Hiniker, Brianne H Daniels, and Marta Margeta.  Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies.  Acta Neuropathologica Communications.  2013; 1: 29.

2013

• Mazen M. Dimachkie, M.D. and Richard J. Barohn, M.D.  Inclusion Body Myositis. Semin Neurol 2012; 32:237-245.  DOI  Http://dx.doi.org/10.1055/s-0032-1329197.  ISSN 0271-8235.
• Jana Zschuntzsch, Joachim Voss, Kim Creus, Stephan Sehmisch, Raghavan Raju, Marinos C. Dalakas, and Jens Schmidt.  Provision o fan Explanation for the Inefficacy of Immunotherapy in Sporadic Inclusion Body Myositis.  Arthritis & Rheumatism.  Vol. 64, No. 12, December 2012, pp 4094-4103.  DOI 10.1002/art.37692.

2012

• Bruno Gualano, Carlos Ugrinowitsch, Manoel Neves Jr., Fernanda R. Lima, Ana Lucia S. Pinto, Gilberto Laurentino, Valmor A.A. Tricoli, Antonio H. Lancha Jr., and Hamilton Roschel.  Vascular Occlusion Training for Inclusion Body Myositis:  A Novel Therapeutic Approach.  Journal of Visualized Experiments.  J Vis Exp. 2010; (40):  1894.

2011

• K.A. Bernhardt, T.H. Oh, K.R. Kaufman.  Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach. Gait Posture (2011), doi 10.1016/i.gaitpost.2010.12.021.

2010

• Valerie Askansas, MD, PhD; W. King Engel, MD; Anna Nogalska, PhD.  Inclusion Body Myositis: A Degenerative Muscle Fiber Associated with Intra-Muscle Fiber Multi-Protein Aggregates, Proteasome Inhibition, Endoplasmic Reticulum Stress and Decreased Lysosomal Degradation. Brain Pathology. 2009; 19: 493-506.
• D. Hilton, A. Miller, M. Parton, J. Holton, C. Sewry, M.G. Hanna.  MRC Centre for Neuromuscular Diseases, IBM Work Shop, London. Neuromuscular Disorders. 2008 June.
• A A Amato & R J Barohn.  Inclusion Body Myositis: Old and New Concepts. Journal of Neurology, Neurosurgery, and Psychiatry. 2009; 80; 1186-1193.
  Mike Recher, Ulrike Sahrbacher, Juliane Bremer, Borge Arndt, Urs Steiner, Adriano Fontana.  Treatment of IBM with Low-Dose IVIG. Rheumatol Int. DOI 10.1007/s00296-009-1290-z.
• Anna Nogalska, Chiara Terracciano, Carla D’Agostino, W. King Engel, Valerie Askansas.  p62/SQSTM1 in IBM. Acta Neuropathol. 2009. 118:407-413.
• Chiara Terracciano, Anna Nogalska, W. King Engel and Valerie Askansas.  Lithium and IBM. Journal Of Neurochemistry. 2010. 112: 389-396.
• Wolfgang Utz, Saskia Schmidt, Jeanette Schulz-Menger, Friedrich Luft, Simone Spuler.  Cardiac Involvement in Sporadic Inclusion-Body Myositis. Circulation Journal of The American Heart Association. 2010;121;706-708. DOI: 10.1161/CIRCULATIONAHA.109.866178
• Steven A. Greenberg.  Theories of the Pathogenesis of Inclusion Body Myositis. Curr Rheumatol Rep. 16 April 2010. DOI 10.1007/s11926-010-0102-5.
• Bruno Gualano, Manoel Neves Jr, Fernanda Rodrigues Lima, Ana Lucia De Sa Pinot, Gilberto Laurentino, Claudia Borges, Luciana Baptista, Guilherme Giannini Artioli, Marcelo Saldanha Aoki, Anslmo Moriscot, Antonio Herbert Lancha Jr, Eloisa Bonfa and Carlos Ugrinowitsch. Resistance Training with Vascular Occlusion in Inclusion Body Myositis: A Case Study. Medicine & Science In Sports & Exercise. 2010. DOI:10.1249/MSS.0b013e3181b18fb8.
• R Sadjadi, M R Rose and Muscle Study Group.  What determines quality of life in inclusion body myositis? Journal of Neurology, Neurosurgrey & Psychiatry. July 2, 2010. DOI: 10.1136/jnnp.2009.183863.
• Thomas E. Lloyd.  Novel therapeutic approaches for inclusion body myositis. Current Opinion in Rheumatology 2010. 22:000-00.

2006-2009

• Janaiah Kota, et al.  Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates. Sci Transl Med 1, 6ra15 (2009); DOL: 10.1126/scitranslmed.3000112.
• Dalakas MC.  Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies. Nature Clinical Practice, Neurology 2 (8): 437-447, 2006
• Drs. Kitazawa, Vasilevko, Cribbs and LaFerla of the University of California.  Live vaccination reduces muscle impairment in mice with IBM-like muscle disease
• Effects of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009 June; 132(6): 1536-1544, published online 2009 March 22. doi: 10. 1093/brain/awp 104.

2001-2005

• Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome. Neuron43,3:321-332, 2004. (See EurekAlert summary article entitled “Immune therapy ‘untangles’ Alzheimers’ Disease”)
• Dalakas MC, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56: 323-327, 2001
• The Muscle Study Group. Randomized pilot trial of BINF1a (Avonex) in patients with inclusion body myositis. Neurology 57: 1566-1570, 2001
• Walter MC, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study. J Neurol 247: 22-28, 2000

1996-2000

• Dalakas MC, et al. Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study. Neurology 48: 712-716, 1997
  1991-1995
• Leff RL, et al. The treatment of inclusion body myositis: A retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine 72 (4): 225-235, 1993